N-[(4-Aminopyrimidin-2-yl)methyl]-5-(furan-2-yl)-1,2-oxazole-3-carboxamide

Catalog No. :
ACGLBO055
CAS No. :
1797275-48-9
Molecular Formula :
C13H11N5O3
Molecular Weight :
285.26

IUPAC Name:N-((4-aminopyrimidin-2-yl)methyl)-5-(furan-2-yl)isoxazole-3-carboxamide

N-[(4-Aminopyrimidin-2-yl)methyl]-5-(furan-2-yl)-1,2-oxazole-3-carboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$677.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-[(4-Aminopyrimidin-2-yl)methyl]-5-(furan-2-yl)-1,2-oxazole-3-carboxamide
IUPAC NameN-((4-aminopyrimidin-2-yl)methyl)-5-(furan-2-yl)isoxazole-3-carboxamide
MDL No.MFCD28139473
Molecular FormulaC13H11N5O3
Molecular Weight285.26
SMILESO=C(C1=NOC(C2=CC=CO2)=C1)NCC3=NC=CC(N)=N3
InChI KeyVQXSCPRRLXBNDH-UHFFFAOYSA-N
SynonymN-[(4-aminopyrimidin-2-yl)methyl]-5-(furan-2-yl)-1,2-oxazole-3-carboxamide;3-Isoxazolecarboxamide, N-[(4-amino-2-pyrimidinyl)methyl]-5-(2-furanyl)-
CAS No.1797275-48-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACGLBO055 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFNJA218 route compound structure diagram
    ACFNJA21898434-06-1 In Stock
  4. Then
  5. ACGLBO055 route product structure diagram
    ACGLBO0551797275-48-9
Inquiry

2. ACGLBO055 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACXAZI387 route compound structure diagram
    ACXAZI38733545-40-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGLBO055 route product structure diagram
    ACGLBO0551797275-48-9
Inquiry

Comments (0)